PIM1 and ovarian cancer: In Tipton et al. (58), it was shown that the differential activity of GBP1 in paclitaxel sensitivity between breast and ovarian cancer cell lines was mediated by interaction with different isoforms of PIM1, wherein a 44 kDa PIM1 isoform was associated with unaltered paclitaxel sensitivity in breast cancer cells while a related 33 kDa PIM1 isoform was associated with induction of paclitaxel resistance in ovarian cancer cells.